Kura Oncology, Inc. Board of Directors

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.

Dr. Mollie Leoni M.D.

Dr. Mollie Leoni M.D.

Chief Medical Officer

Ms. Kathleen Ford

Ms. Kathleen Ford

Chief Operating Officer

Ms. Teresa Brophy Bair Esq., J.D.

Ms. Teresa Brophy Bair Esq., J.D.

Chief Legal Officer & Corporate Secretary

Mr. Thomas Doyle

Mr. Thomas Doyle

Senior Vice President of Finance & Accounting

Dr. Roger Bakale Ph.D.

Dr. Roger Bakale Ph.D.

Senior Vice President of Manufacturing & Supply Chain

Dr. Francis J. Burrows Ph.D.

Dr. Francis J. Burrows Ph.D.

Chief Scientific Officer

Ms. Maureen Clancy M.B.A.

Ms. Maureen Clancy M.B.A.

VP and Global Head of Program Leadership & Project Management

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.